Log in

NASDAQ:VTVTvTv Therapeutics Stock Price, Forecast & News

$1.74
-0.05 (-2.79 %)
(As of 04/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.68
Now: $1.74
$1.80
50-Day Range
$1.63
MA: $2.55
$3.75
52-Week Range
$1.23
Now: $1.74
$4.23
Volume59,369 shs
Average Volume217,788 shs
Market Capitalization$113.55 million
P/E RatioN/A
Dividend YieldN/A
Beta-2.41
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease. It is also developing TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase IIb clinical trials to treat type 2 diabetes, as well as is in Phase II clinical trials for treating type 1 diabetes; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. In addition, the company is developing a portfolio of investigational drug candidates, such as HPP737 and HPP971 to treat inflammatory disorders. It has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
Read More
vTv Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.82 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VTVT
CUSIPN/A
Phone336-841-0300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.76 million
Book Value($0.77) per share

Profitability

Net Income$-13,040,000.00
Net Margins-490.27%

Miscellaneous

Employees52
Market Cap$113.55 million
Next Earnings Date5/6/2020 (Estimated)
OptionableNot Optionable

Receive VTVT News and Ratings via Email

Sign-up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter.


vTv Therapeutics (NASDAQ:VTVT) Frequently Asked Questions

How has vTv Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

vTv Therapeutics' stock was trading at $2.43 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VTVT shares have decreased by 28.4% and is now trading at $1.74. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of vTv Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for vTv Therapeutics.

When is vTv Therapeutics' next earnings date?

vTv Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for vTv Therapeutics.

How were vTv Therapeutics' earnings last quarter?

vTv Therapeutics Inc (NASDAQ:VTVT) issued its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.06) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.12) by $0.06. The biotechnology company had revenue of $3.38 million for the quarter, compared to analysts' expectations of $2.06 million. View vTv Therapeutics' earnings history.

What price target have analysts set for VTVT?

2 brokerages have issued 12-month price objectives for vTv Therapeutics' shares. Their forecasts range from $6.00 to $8.00. On average, they expect vTv Therapeutics' share price to reach $7.00 in the next year. This suggests a possible upside of 302.3% from the stock's current price. View analysts' price targets for vTv Therapeutics.

What are Wall Street analysts saying about vTv Therapeutics stock?

Here are some recent quotes from research analysts about vTv Therapeutics stock:
  • 1. According to Zacks Investment Research, "vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company's drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. " (3/31/2020)
  • 2. HC Wainwright analysts commented, "Our $5 PT was derived by using a weighted-average cost of capital of 24% for vTv to discount free cash flows from annual sales and royalty payments of azeliragon and TPP399 for each year and dividing them by our projected number of shares for each year to account for the effects of share dilution, and then factoring in a 1% terminal growth rate and 26% clinical program probability of success." (8/16/2019)

Has vTv Therapeutics been receiving favorable news coverage?

Media stories about VTVT stock have trended very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. vTv Therapeutics earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutvTv Therapeutics.

Who are some of vTv Therapeutics' key competitors?

What other stocks do shareholders of vTv Therapeutics own?

Who are vTv Therapeutics' key executives?

vTv Therapeutics' management team includes the following people:
  • Mr. Jeffrey B. Kindler, Exec. Chairman (Age 63)
  • Mr. Stephen L. Holcombe, Pres & CEO (Age 62)
  • Mr. Rudy C. Howard CPA, B.A., CPA, Exec. VP & CFO (Age 61)
  • Dr. Carmen Valcarce Ph.D., Chief Scientific Officer & Exec. VP
  • Ms. Robin E. Abrams, Exec. VP & Gen. Counsel (Age 55)

When did vTv Therapeutics IPO?

(VTVT) raised $125 million in an IPO on Thursday, July 30th 2015. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

What is vTv Therapeutics' stock symbol?

vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."

How do I buy shares of vTv Therapeutics?

Shares of VTVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is vTv Therapeutics' stock price today?

One share of VTVT stock can currently be purchased for approximately $1.74.

How big of a company is vTv Therapeutics?

vTv Therapeutics has a market capitalization of $113.55 million and generates $2.76 million in revenue each year. The biotechnology company earns $-13,040,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. vTv Therapeutics employs 52 workers across the globe. View additional information about vTv Therapeutics.

What is vTv Therapeutics' official website?

The official website for vTv Therapeutics is http://www.vtvtherapeutics.com/.

How can I contact vTv Therapeutics?

vTv Therapeutics' mailing address is 3980 PREMIER DR SUITE 310, HIGH POINT NC, 27265. The biotechnology company can be reached via phone at 336-841-0300 or via email at [email protected]

This page was last updated on 4/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel